SOD1 and amyotrophic lateral sclerosis: In the case of NfL, while it has been effective in tracking disease progression in disorders such as multiple sclerosis and amyotrophic lateral sclerosis, studies such as those involving the anti-SOD1 therapy in ALS failed to show a clear correlation between NfL reduction and clinical improvement, raising concerns about its reliability as a surrogate endpoint [12].